Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
15 pending office actions • 10 art units • 15 examiners • 0 of 15 (0%) have an AI response strategy ready • 19 patents granted in the last 365 days
National University Corporation Hokkaido University is currently managing 15 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio is highly diversified, with the 15 actions spread across 15 distinct examiners. Furthermore, these matters are distributed among 10 distinct art units, indicating a very broad technical range that spans many different specialized divisions at the patent office.
KRUPICKA, ADAM C is the busiest examiner for the university, currently handling 1 pending office action. In this portfolio, every 1 of the 15 pending actions is assigned to a different examiner, meaning no single official manages more than 1 case. The presence of 10 distinct art units for 15 actions highlights the complexity of the university's research output, as it requires engagement with many different specialized units. Practitioners must be prepared to navigate a wide array of examiner preferences and art unit standards across this extensive and varied biotechnology portfolio. This high level of decentralization requires a robust management strategy to ensure that the prosecution of each individual matter remains consistent with the university's broader intellectual property goals.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (7%) |
| §103 only | 2 (13%) |
| §102 only | 1 (7%) |
| §112 only | 2 (13%) |
| Double-patenting + other | 3 (20%) |
| Multi-statute (no §101) | 6 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KRUPICKA, ADAM C | 1 | 62.1% | +27.0% |
| PIPIC, ALMA | 1 | 54.6% | +54.7% |
| STAHL, MICHAEL J | 1 | 90.1% | +7.5% |
| LEE, HOI YAN NMN | 1 | 38.4% | +75.9% |
| CHERNYSHEV, OLGA N | 1 | 54.5% | +34.4% |
| ARCIERO, ADAM A | 1 | 65.1% | -17.6% |
| HIRAKIS, SOPHIA P | 1 | 56.1% | +73.5% |
| BUTTICE, AUDREY L | 1 | 47.9% | +25.9% |
| RONEY, CELESTE A | 1 | 62.8% | +17.5% |
| NGUYEN, KEVIN NMN | 1 | 82.5% | +8.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18810979 | OPTICAL FILTER, METHOD OF MANUFACTURING OPTICAL FILTER, METHOD OF DESIGNING, DESIGN APPARATUS, AND NON-TRANSITORY COMPUTER-READABLE RECORDING MEDIUM | STAHL, MICHAEL J | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18024955 | METHOD FOR DIAGNOSING NONALCOHOLIC STEATOHEPATITIS | BOWERS, ERIN M | 27d |
| 18293199 | PHARMACEUTICAL COMPOSITION FOR TREATING PERIPHERAL NERVE INJURY | CHERNYSHEV, OLGA N | — |
| 18578874 | SULFIDE SOLID ELECTROLYTE | ARCIERO, ADAM A | — |
| 18282351 | METHOD FOR PRODUCING LAYERED COMPOSITE METAL OXIDE CRYSTAL MATERIAL | NGUYEN, KEVIN NMN | — |
| 18260488 | LIGNIN-DEGRADING CATALYST, METHOD FOR MANUFACTURING SAME, METHOD FOR DEGRADING LIGNIN, AND METHOD FOR REGENERATING LIGNIN-DEGRADING CATALYST | SAWYER, JENNIFER C | — |
| 18154575 | JAPANESE ENCEPHALITIS PREVENTIVE AGENT AND JAPANESE ENCEPHALITIS VACCINE AGENT | QIAN, CELINE X | — |
| 18052100 | TREATMENT DEVICE | MORAN, EDWARD JOHN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18921804 | METAL POROUS BODY, NITROUS OXIDE DECOMPOSITION ELEMENT, AND NITROUS OXIDE DECOMPOSITION APPARATUS | KRUPICKA, ADAM C | 34d |
| 18851300 | LIPID NANOPARTICLES | PIPIC, ALMA | — |
| 18708483 | ANTIVIRAL AGENT | LEE, HOI YAN NMN | — |
| 18293199 | PHARMACEUTICAL COMPOSITION FOR TREATING PERIPHERAL NERVE INJURY | CHERNYSHEV, OLGA N | — |
| 18396272 | COMPOUND, MANUFACTURING METHOD THEREFOR, ANTIMICROBIAL AGENT, AND MEDICINAL DRUG | HIRAKIS, SOPHIA P | — |
| 18259348 | GFRALPHA1-CONTAINING NEURITE OUTGROWTH PROMOTER AND PHARMACEUTICAL COMPOSITION FOR INDUCING NERVE REGENERATION | BUTTICE, AUDREY L | — |
| 18561555 | LIPID NANOPARTICLES | RONEY, CELESTE A | — |
| Art Unit | Apps |
|---|---|
| 1784 | 1 |
| 1617 | 1 |
| 1623 | 1 |
| 1612 | 1 |
| 1752 | 1 |
| 1691 | 1 |
| 1653 | 1 |
| 1637 | 1 |
| 3772 | 1 |
| 1767 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18921804 | METAL POROUS BODY, NITROUS OXIDE DECOMPOSITION ELEMENT, AND NITROUS OXIDE DECOMPOSITION APPARATUS | KRUPICKA, ADAM C | 1784 | §112 | Final Rejection | 34d | Pending | Oct 21, 2024 |
| 18851300 | LIPID NANOPARTICLES | PIPIC, ALMA | 1617 | §112DP | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18810979 | OPTICAL FILTER, METHOD OF MANUFACTURING OPTICAL FILTER, METHOD OF DESIGNING, DESIGN APPARATUS, AND NON-TRANSITORY COMPUTER-READABLE RECORDING MEDIUM | STAHL, MICHAEL J | — | §102 | Non-Final OA | — | Pending | Aug 21, 2024 |
| 18708483 | ANTIVIRAL AGENT | LEE, HOI YAN NMN | — | §102§112DP | Non-Final OA | — | Pending | May 08, 2024 |
| 18293199 | PHARMACEUTICAL COMPOSITION FOR TREATING PERIPHERAL NERVE INJURY | CHERNYSHEV, OLGA N | — | §102§112 | Non-Final OA | — | Pending | Jan 29, 2024 |
| 18578874 | SULFIDE SOLID ELECTROLYTE | ARCIERO, ADAM A | — | §102§103 | Non-Final OA | — | Pending | Jan 12, 2024 |
| 18396272 | COMPOUND, MANUFACTURING METHOD THEREFOR, ANTIMICROBIAL AGENT, AND MEDICINAL DRUG | HIRAKIS, SOPHIA P | 1623 | §112 | Non-Final OA | — | Pending | Dec 26, 2023 |
| 18259348 | GFRALPHA1-CONTAINING NEURITE OUTGROWTH PROMOTER AND PHARMACEUTICAL COMPOSITION FOR INDUCING NERVE REGENERATION | BUTTICE, AUDREY L | — | §103 | Non-Final OA | — | Pending | Dec 06, 2023 |
| 18561555 | LIPID NANOPARTICLES | RONEY, CELESTE A | 1612 | §103DP | Final Rejection | — | Pending | Nov 16, 2023 |
| 18282351 | METHOD FOR PRODUCING LAYERED COMPOSITE METAL OXIDE CRYSTAL MATERIAL | NGUYEN, KEVIN NMN | 1752 | §103§112 | Final Rejection | — | Pending | Sep 15, 2023 |
| 18260488 | LIGNIN-DEGRADING CATALYST, METHOD FOR MANUFACTURING SAME, METHOD FOR DEGRADING LIGNIN, AND METHOD FOR REGENERATING LIGNIN-DEGRADING CATALYST | SAWYER, JENNIFER C | 1691 | §102§112 | Non-Final OA | — | Pending | Jul 06, 2023 |
| 18024955 | METHOD FOR DIAGNOSING NONALCOHOLIC STEATOHEPATITIS | BOWERS, ERIN M | 1653 | §101 | Final Rejection | 27d | Pending | Mar 06, 2023 |
| 18154575 | JAPANESE ENCEPHALITIS PREVENTIVE AGENT AND JAPANESE ENCEPHALITIS VACCINE AGENT | QIAN, CELINE X | 1637 | §102§112 | Non-Final OA | — | Pending | Jan 13, 2023 |
| 18052100 | TREATMENT DEVICE | MORAN, EDWARD JOHN | 3772 | §102§103§112 | Final Rejection | — | Pending | Nov 02, 2022 |
| 17802772 | BLOCK COPOLYMER AND METHOD FOR PRODUCING SAME | MCCULLEY, MEGAN CASSANDRA | 1767 | §103 | Final Rejection | — | Pending | Aug 26, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial